These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32891532)

  • 1. Pancreatic neuroendocrine carcinoma G3 may be heterogeneous and could be classified into two distinct groups.
    Tanaka H; Hijioka S; Hosoda W; Ueno M; Kobayashi N; Ikeda M; Ito T; Kodama Y; Morizane C; Notohara K; Taguchi H; Kitano M; Komoto I; Tsuji A; Hashigo S; Kanno A; Miyabe K; Takagi T; Ishii H; Kojima Y; Yoshitomi H; Yanagimoto H; Furuse J; Mizuno N
    Pancreatology; 2020 Oct; 20(7):1421-1427. PubMed ID: 32891532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rb Loss and
    Hijioka S; Hosoda W; Matsuo K; Ueno M; Furukawa M; Yoshitomi H; Kobayashi N; Ikeda M; Ito T; Nakamori S; Ishii H; Kodama Y; Morizane C; Okusaka T; Yanagimoto H; Notohara K; Taguchi H; Kitano M; Yane K; Maguchi H; Tsuchiya Y; Komoto I; Tanaka H; Tsuji A; Hashigo S; Kawaguchi Y; Mine T; Kanno A; Murohisa G; Miyabe K; Takagi T; Matayoshi N; Yoshida T; Hara K; Imamura M; Furuse J; Yatabe Y; Mizuno N
    Clin Cancer Res; 2017 Aug; 23(16):4625-4632. PubMed ID: 28455360
    [No Abstract]   [Full Text] [Related]  

  • 3. Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas?
    Hijioka S; Hosoda W; Mizuno N; Hara K; Imaoka H; Bhatia V; Mekky MA; Tajika M; Tanaka T; Ishihara M; Yogi T; Tsutumi H; Fujiyoshi T; Sato T; Hieda N; Yoshida T; Okuno N; Shimizu Y; Yatabe Y; Niwa Y; Yamao K
    J Gastroenterol; 2015 May; 50(5):564-72. PubMed ID: 25142799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinum-Based Treatment for Well- and Poorly Differentiated Pancreatic Neuroendocrine Neoplasms.
    Pulvirenti A; Raj N; Cingarlini S; Pea A; Tang LH; Luchini C; Chou JF; Grego E; Marinova I; Capanu M; Landoni L; Scarpa A; Allen PJ; Klimstra DS; Reidy-Lagunes DL
    Pancreas; 2021 Feb; 50(2):138-146. PubMed ID: 33565789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated.
    Raj N; Valentino E; Capanu M; Tang LH; Basturk O; Untch BR; Allen PJ; Klimstra DS; Reidy-Lagunes D
    Pancreas; 2017 Mar; 46(3):296-301. PubMed ID: 27759713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.
    Umetsu SE; Kakar S; Basturk O; Kim GE; Chatterjee D; Wen KW; Hale G; Shafizadeh N; Cho SJ; Whitman J; Gill RM; Jones KD; Navale P; Bergsland E; Klimstra D; Joseph NM
    Mod Pathol; 2023 Mar; 36(3):100065. PubMed ID: 36788102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms.
    Elvebakken H; Hjortland GO; Garresori H; Andresen PA; Janssen EAM; Vintermyr OK; Lothe IMB; Sorbye H
    J Neuroendocrinol; 2023 Apr; 35(4):e13256. PubMed ID: 37017614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Eighth Edition of the American Joint Committee on Cancer Distant Metastases Stage Classification for Metastatic Pancreatic Neuroendocrine Tumors Might Be Feasible for Metastatic Pancreatic Ductal Adenocarcinomas.
    Wen J; Chen J; Liu D; Xu X; Fan M; Zhang Z
    Neuroendocrinology; 2020; 110(5):364-376. PubMed ID: 31357196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms.
    Zhu X; Salhab M; Tomaszewicz K; Meng X; Mathew C; Bathini V; Switzer B; Walter O; Cosar EF; Wang X; Lambert LA; Hutchinson LM
    Hum Pathol; 2019 Mar; 85():260-269. PubMed ID: 30458197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Impact of KRAS and GNAS Analysis Added to CEA and Cytology in Pancreatic Cystic Fluid Obtained by EUS-FNA.
    Faias S; Duarte M; Albuquerque C; da Silva JP; Fonseca R; Roque R; Dias Pereira A; Chaves P; Cravo M
    Dig Dis Sci; 2018 Sep; 63(9):2351-2361. PubMed ID: 29796909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
    Fazio N; Milione M
    Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma.
    Shamir ER; Devine WP; Pekmezci M; Umetsu SE; Krings G; Federman S; Cho SJ; Saunders TA; Jen KY; Bergsland E; Jones K; Kim GE; Kakar S; Chiu CY; Joseph NM
    Mod Pathol; 2019 Feb; 32(2):290-305. PubMed ID: 30237525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study.
    Kim H; An S; Lee K; Ahn S; Park DY; Kim JH; Kang DW; Kim MJ; Chang MS; Jung ES; Kim JM; Choi YJ; Jin SY; Chang HK; Cho MY; Kang YK; Kang M; Ahn S; Kim YW; Hong SM;
    Cancer Res Treat; 2020 Jan; 52(1):263-276. PubMed ID: 31319641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of rapid on-site evaluation specimens from endoscopic ultrasound-guided fine-needle aspiration for cancer gene panel testing: A retrospective study.
    Ishizawa T; Makino N; Matsuda A; Kakizaki Y; Kobayashi T; Ikeda C; Sugahara S; Tsunoda M; Ueno Y
    PLoS One; 2020; 15(1):e0228565. PubMed ID: 31999789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of cytologic differentiation in high-grade pancreatic neuroendocrine neoplasms: A multi-institutional study.
    Sigel CS; Krauss Silva VW; Reid MD; Chhieng D; Basturk O; Sigel KM; Daniel TD; Klimstra DS; Tang LH
    Cancer Cytopathol; 2018 Jan; 126(1):44-53. PubMed ID: 29044913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Responsiveness of well-differentiated PanNET G3 to platinum-based chemotherapy: a case report].
    Kojima E; Kuba H; Matsumura M
    Nihon Shokakibyo Gakkai Zasshi; 2019; 116(11):952-959. PubMed ID: 31708508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution.
    Yang M; Zeng L; Ke NW; Tan CL; Tian BL; Liu XB; Xiang B; Zhang Y
    BMC Cancer; 2020 Sep; 20(1):906. PubMed ID: 32962649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Local Recurrence of Pancreatic Cancer by KRAS Mutation Analysis Using Washes from Endoscopic Ultrasound-Guided Fine-Needle Aspiration.
    Matsumoto K; Kato H; Nouso K; Ako S; Kinugasa H; Horiguchi S; Saragai Y; Takada S; Yabe S; Muro S; Uchida D; Tomoda T; Okada H
    Dig Dis Sci; 2020 Oct; 65(10):2907-2913. PubMed ID: 31897893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.